About this source
- Kind
- Research
- Design
- Human clinical trial
- Population
- Autism spectrum disorder, long-term intranasal oxytocin users, pooled across included trials
- Primary or secondary
- secondary
- Peer review
- peer reviewed
- Retraction status
- None known
- Date checked
- 14 August 2026
Limitations
Long-term/repeated-dose safety data specifically is described in the broader literature as sparser than acute-dose safety data.
Cited in
Intranasal adverse-event meta-analysis
Oxytocin · Safety finding
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.